Treatment candidate for limp-girdle muscular dystrophy receives Rare Pediatric Designation
June 18th 2024The company also announced that it has surpassed its interim analysis enrollment target and expects topline phase 3 data from the FORTIFY study (NCT05775848) among individuals with LGMD21/R9 in 2025.